News
DICE
31.20
+3.24%
0.98
BAND, PRTK and OTLY are among after hour movers
Seeking Alpha · 01/26 22:53
DICE Therapeutics: Risks To Reversal Rally Noted In Market Data (Technical Analysis)
Seeking Alpha · 01/25 05:38
DICE Therapeutics: Oral Drug Of Proven IL-17 Target
Seeking Alpha · 01/24 09:41
Healthcare Outlook 2023
Seeking Alpha · 01/23 15:02
Biotech Bonanza: 2023 Biotech Outlook As The Fed Remains Hawkish
Seeking Alpha · 01/09 14:55
Where DICE Therapeutics Stands With Analysts
Benzinga · 11/15/2022 16:23
Guggenheim Initiates Coverage On DICE Therapeutics with Buy Rating, Announces Price Target of $65
Benzinga · 11/15/2022 12:32
Blue Star (NASDAQ: BSFC) Insiders Are Buying Stock
Benzinga · 11/11/2022 13:41
DICE Therapeutics GAAP EPS of -$0.55 beats by $0.05
Seekingalpha · 11/09/2022 22:22
DICE Therapeutics Q3 EPS $(0.55) Up From $(2.15) YoY
Benzinga · 11/09/2022 22:15
-- Earnings Flash (DICE) DICE THERAPEUTICS Reports Q3 Loss $-0.55
-- Earnings Flash (DICE) DICE THERAPEUTICS Reports Q3 Loss $-0.55
MT Newswires · 11/09/2022 16:11
DICE Therapeutics to Present at Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (Nasdaq: DICE), a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic dise...
GlobeNewswire · 11/03/2022 20:05
Candel, Calliditas top healthcare gainers; Immunic, Tenet lead losers pack
Seekingalpha · 10/21/2022 14:00
Around $60 Million Bet On DICE Therapeutics? 3 Stocks Insiders Are Buying
Benzinga · 10/20/2022 11:45
Jim Cramer Says People Are Betting Against Stock Up 84% This Year: It Could Be An 'Up Big, Down Big Situation'
On CNBC’s "Mad Money Lightning Round," Jim Cramer said he can’t recommend Dice Therapeutics Inc (NASDAQ: DICE) as the company is "losing money hand over fist."
Benzinga · 10/18/2022 12:04
BRIEF-Dice Therapeutics Announces Closing Of Upsized Public Offering
Reuters · 10/17/2022 20:12
DICE Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
SOUTH SAN FRANCISCO, Calif., Oct. 17, 2022 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (Nasdaq: DICE), a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic dise...
GlobeNewswire · 10/17/2022 20:05
Institutional investors are DICE Therapeutics, Inc.'s (NASDAQ:DICE) biggest bettors and were rewarded after last week's US$875m market cap gain
Every investor in DICE Therapeutics, Inc. ( NASDAQ:DICE ) should be aware of the most powerful shareholder groups. And...
Simply Wall St. · 10/16/2022 13:50
DICE Therapeutics prices ~$300M stock offering
Seekingalpha · 10/13/2022 09:13
DICE Therapeutics Late Wednesday Announces Pricing Of Upsized $300M Public Offering Of 8,219,178 Shares Of Common Stock At A Price Of $36.50/Share
 DICE Therapeutics, Inc. (NASDAQ:DICE), a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and
Benzinga · 10/13/2022 05:16
More
Webull provides a variety of real-time DICE stock news. You can receive the latest news about Dice Therapeutics, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About DICE
DICE Therapeutics, Inc., formerly Dice Molecules Holdings LLC, is a biopharmaceutical company. The Company leverages its technology platform to build a pipeline of oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. It is focused on developing oral therapeutics against targets in immunology. The Company’s platform, which it refers to as DELSCAPE, is designed to discover selective oral small molecules with the potential to modulate protein-protein interactions (PPIs) as effectively as systemic biologics. Its lead therapeutic candidate, DC-806, is an oral antagonist of the pro-inflammatory signaling molecule, interleukin-17 (IL-17), which is a validated drug target implicated in a variety of immunology indications. The Company is also developing oral therapeutic candidates targeting α4ß7 integrin and αVß1/αVß6 integrin for the treatment of inflammatory bowel disease (IBD) and idiopathic pulmonary fibrosis (IPF).